SORRENTO THERAPEUTICS, INC.

Analyst Reco. Sorrento Therapeutics, Inc.

Equities

SRNE

US83587F2020

Market Closed - OTC Markets Other stock markets 01:29:23 30/04/2024 am IST			5-day change	1st Jan Change
0.0145 ^USD	+5.84%		-3.33%	-88.26%

15/03	Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	MT
12/03	News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dawson James Downgrades Sorrento Therapeutics to Neutral Rating From Buy	13/23/13	MT
Cantor Fitzgerald Initiates Sorrento Therapeutics at Overweight With $5 Price Target	02/22/02	MT
HC Wainwright Adjusts Sorrento Therapeutics' Price Target to $20 From $26, Reiterates Buy Rating	25/22/25	MT
SORRENTO THERAPEUTICS : HC Wainwright Adjusts Sorrento Therapeutics' Price Target to $26 From $30, Keeps Buy Rating	09/21/09	MT
Sorrento Therapeutics, Inc. Announces Positive Results of Phase 1b Study of COVI-MSC Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate	20/21/20	CI
SORRENTO THERAPEUTICS : B. Riley Starts Sorrento Therapeutics at Buy With $26 Price Target	29/21/29	MT
SORRENTO THERAPEUTICS : Alliance Global Partners Starts Sorrento Therapeutics at Buy With $35 Price Target	21/21/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer